Serum microRNA profiling to distinguish papillary thyroid cancer from benign thyroid masses. Issue 1 (December 2015)

• Record Type: Journal Article
• Authors: Graham, M.; Hart, Robert; Douglas, Susan; Makki, Fawaz; Pinto, Devanand; Butler, Angela; Bullock, Martin; Rigby, Matthew; Trites, Jonathan; Taylor, S.; Singh, Rama
• Is Part Of: Journal of otolaryngology - head & neck surgery. Volume 44:Issue 1(2015)
• Page Start: 1
• Page End: 9
• Publication Date: 2015-12
• Subjects: Papillary thyroid cancer -- MicroRNA -- Serum testing -- Biomarkers; Head -- Surgery -- Periodicals; Neck -- Surgery -- Periodicals; Otolaryngology -- Periodicals; Otorhinolaryngologic Surgical Procedures -- Periodicals; Head -- Surgery; Neck -- Surgery; Otolaryngology; Periodicals; 617.51005
• DOI: 10.1186/s40463-015-0083-5
• Languages: English
• ISSNs: 1916-0208

Abstract

Abstract Objectives Papillary thyroid cancer (PTC) is increasing in incidence. Fine needle aspiration is the gold standard for diagnosis, but results can be indeterminate. Identifying tissue and serum biomarkers, like microRNA, is therefore desirable. We sought to identify miRNA that is differentially expressed in the serum of patients with PTC. Methods Serum miRNA was quantified in 31 female thyroidectomy patients: 13 with benign disease and 18 with PTC. qPCR results were compared for significant fold-changes in 175 miRNAs, against a pooled control. Results 128 miRNA qualified for analysis. There were identifiable fold-changes in miRNA levels between benign and control, and between PTC and control. There were statistically significant fold changes in the level of four miRNAs between benign and PTC: hsa-miR-146a-5p and hsa-miR-199b-3p were down-regulated, while hsa-let7b-5p and hsa-miR-10a-5p were up-regulated. Conclusions MicroRNA is differentially expressed in the serum of patients with PTC. Serum miRNA has the potential to aid in thyroid cancer diagnosis.